Entries by groupH

UPDATE: our take on CMS’s latest memo on CAR-T reimbursement

Earlier in the year, we reviewed the reimbursement challenges that CAR-T therapies are experiencing in the US, assessed some of the proposed solutions, and outlined Payers’ expectations from next-generation CAR-T therapies. Click here to see the original analysis. CMS published a memo providing an update to CAR-T reimbursement in early August that included a number […]

Forecasting and Data Analytics Round Table Discussions – EphMRA 2019

Following the positive feedback from the inaugural Forecasting Roundtable Discussion from 2018, Erik Holzinger/groupH facilitated another 1-hour discussion together with Pascal Olier/Pierre Fabre on the topic of Forecasting and Data Analytics. There was a large group of attendees consisting of some very experienced individuals from both the pharma company and agency side, with regard to […]

groupH springtime gathering

Taking the EU part of groupH to the gorgeous Lake District during a wet and windy few days – we enjoyed an outdoor day, long walks and talks with almost no rain nevertheless, cosy pubs and good food.              

CAR-T Reimbursement in the US – Challenges and an Assessment of Potential Solutions

CAR-T cell therapy has recently arisen as an exciting and innovative therapeutic modality. A wave of new biotechs have been established, several hundreds of clinical trials are underway, and multi-billion-dollar acquisitions have occurred. Despite rapid scientific and clinical advancements, Medicare reimbursement during these initial launch years has been underwhelming, particularly in the in-patient setting where […]

groupH seasonal gathering 2018

At the close of a very busy last month of the year the groupH team got together at Berry Bros. & Rudd, Britain’s oldest wine and spirit merchant, in London’s St James’s. Deep underground in one of their cosy cellars, it was a great opportunity to connect with colleagues, old and new and to enjoy […]

EU Payer Opinion on Assessing Value in Rare Diseases

groupH asked senior EU payers to comment on how they assess Value in Rare Diseases and how it is different from more prevalent indications. Click below to watch one of the interviews, with Bruno Falissard.  Bruno is a former member of the Transparency Commission at HAS, Psychiatrist and Biostatistician, and Head of Research Unit Inserm […]

Two countries divided by a common language?

groupH explored the different approaches and philosophies behind Market Research and Consulting from the perspective of individuals with a Market Research, Strategy Consulting and Pharma background through a short online survey. Please find the results and insights and a graphic showing how the MR and Consulting value chain, capabilities, project types and underlying value driving […]

Looking for and Quantifying Value in Rare Diseases: 6th November, 2018

groupH was selected to present on the topic of Looking for and Quantifying Value in Rare Diseases at an EphMRA meeting in Basel on 6th November, 2018. Rare diseases present a number of challenges for manufacturers, which are absent in more prevalent conditions.  So which approach should you take when trying to determine value? In his […]